Ebola Virus Disease (EVD): What matters for morbidity, mortality, and quality of life
• Bold recommendation: If you suspect EVD, immediately isolate with full contact precautions and urgently arrange rRT-PCR testing; start aggressive IV fluids/electrolyte resuscitation and give an approved anti-Ebola monoclonal antibody (REGN-EB3/Inmazeb) as early as possible—these steps most reduce death and long-term disability 1.
What it is
- Filovirus infection (Zaire ebolavirus most lethal) with untreated case-fatality up to 70–90% and rapid progression to shock and multiorgan failure if not promptly treated 1.
Transmission and incubation
- Zoonotic spillover (likely fruit bats; also nonhuman primates/duikers), then human-to-human via direct contact with blood/body fluids, contaminated surfaces, and during care and burial practices 1.
- Incubation ~8.5 days on average (range up to 21) 2.
- Viral persistence: semen months–years (documented sexual transmission up to 470 days post-onset); virus detected in ocular fluid, CNS, placenta, breast milk—implications for relapse and secondary transmission 1.
Clinical presentation (time course that predicts risk)
- Day 0–3: “Dry” symptoms—fever, headache, myalgias, arthralgias 1.
- ~Day 4 onward: “Wet” symptoms—profuse vomiting/diarrhea (up to 10 L/day), leading to severe dehydration, electrolyte derangements, AKI, shock; hemorrhage in ~50%, usually late 1.
- Labs: leukopenia, lymphopenia, elevated AST/ALT; DIC markers in severe disease 1.
- Fatal cases often die 7–10 days after onset from multiorgan failure 1.
Diagnosis (do this, in order, to protect staff and patients)
- Immediately isolate; collect only essential specimens with full PPE.
- Test: rRT-PCR for EBOV RNA is the standard. Antigen rapid tests may aid triage but do not replace PCR 3.
- Minimize transport; use bedside diagnostics when possible; imaging at bedside or in controlled, designated sessions if essential to care 4.
Treatment (highest impact on survival and QOL)
- Immediate supportive care (do not delay):
- Large-volume IV crystalloids; correct K+, Na+, Ca2+ aggressively.
- Manage shock (fluids, vasopressors), AKI (consider RRT at bedside with dedicated machines), and hypoxia (oxygen; airway only if essential due to exposure risk) 4, 1.
- Early, protocolized supportive care alone can lower mortality to ~40% 1.
- Specific anti-EBOV therapy (prioritize the best evidence):
- Procedures and ICU care with exposure control:
Common pitfalls to avoid:
- Delayed fluids/electrolytes and delayed monoclonal therapy—both raise mortality 1.
- Unnecessary patient transport; non-designated equipment use; lapses in PPE donning/doffing—raise nosocomial transmission risk 4.
- Assuming recovery ends infectious risk—counsel on semen persistence and breast milk; arrange testing and safe-sex guidance 1.
Prevention (who to vaccinate, and how to protect others)
- Vaccine: Ervebo (rVSVΔG-ZEBOV-GP) is the only FDA-licensed vaccine (for Zaire ebolavirus).
- Survivors:
- Semen testing and safer sex: EBOV RNA can persist >1 year (up to 965 days documented); sexual transmission documented at 199 and 470 days. Use condoms and follow testing programs until two consecutive negatives 1.
- Breastfeeding: EBOV detected up to 16 months; avoid breastfeeding until virologically cleared per public health guidance 1.
- Health-care infection control:
- Strict contact and droplet precautions with full PPE; consider respirators for high-risk procedures; designated equipment and areas; trained monitor for compliance 4.
How to act when you suspect a case (step-by-step)
- Isolate immediately; notify infection control and public health 4.
- Don full PPE; limit staff exposure; perform only essential tasks.
- Draw labs with biosafety protocols; order EBOV rRT-PCR.
- Start high-volume IV fluids, correct electrolytes, treat shock; begin antiemetics and antidiarrheals; initiate vasopressors if needed.
- Administer REGN-EB3 as early as possible for confirmed or highly probable Zaire ebolavirus cases per FDA/availability 1.
- Manage complications (AKI with bedside RRT, coagulopathy, hypoxia) while minimizing aerosol-generating procedures 4.
- Plan survivor follow-up: eye/CNS symptoms, renal monitoring, semen testing, reproductive counseling to reduce late morbidity and transmission 1.
Notes on evidence strength and nuances:
- Highest-quality, most recent actionable guidance for mortality/QOL reduction: ACIP MMWR (2021) on vaccine/prevention and RCT monoclonal antibody data with FDA approval of REGN-EB3; early supportive care impact repeatedly affirmed 1.
- Infection-control logistics in HLIU/ICU are guided by consensus recommendations; evidence for aerosol risks in EVD is indirect—still treat aerosol-generating procedures as high risk to protect staff 4.
- Epidemiologic parameters (incubation, time-to-death) are consistent across syntheses; variability reflects outbreak context 2.